A Study to Evaluate the Efficacy, Safety, and Tolerability of ASC30 Tablets in Participants With Type 2 Diabetes Mellitus

A phase 2 trial registered on ClinicalTrials.gov. The registry status is completed. It enrolled 100 participants.

Also called NCT07321678

  • Study
  • In this atlas

Overview

Design
Interventional study; randomized; quadruple masking; primary purpose treatment
Phase
Phase 2
Enrolled
  • 100 participants (enrolled count) (from the registry)
Sponsor
Ascletis Pharma (China) Co., Limited (from the registry)
Registry
  • NCT NCT07321678
Started
(actual) (from the registry)
Primary completion
(actual) (from the registry)
Completion
(actual) (from the registry)
Countries
United States (from the registry)
Registry status
  • Completed (from the registry)

Technical summary

Registry record NCT07321678. Randomized; quadruple masking; primary purpose treatment. Start 2026-01-22 (actual); primary completion 2026-08-10 (actual). Results not posted.

The registry's words

Labels as the registry gives them, not rewritten.

Brief title
A Study to Evaluate the Efficacy, Safety, and Tolerability of ASC30 Tablets in Participants With Type 2 Diabetes Mellitus
Condition
T2DM (Type 2 Diabetes Mellitus)
Intervention (Drug)
ASC30 tablets
Intervention (Drug)
Placebo
Lead sponsor
Ascletis Pharma (China) Co., Limited (class: industry)

Record details

Record id
cardio:ct-nct07321678
Content hash
42a1ac6f22b9f8399d943277ce27c7ad612697154ca5412fd53c08b3f0b86aee